Two Norwegian companies are combining their ingredients in a new combination claiming cardiovascular health benefits.
Just in time for an official rollout at Natural Products Expo West (Anaheim, CA), NattoPharma ASA (Hovik, Norway) and Hofseth BioCare (HBC; Alesund, Norway) have announced a new combination of their ingredients “to create a highly differentiable offering for heart health products,” according to a press release. NattoPharma’s MenaQ7 Vitamin K2 and HBC’s OmeGo EFA from Salmon Oil are the two components in the new blend designed to support cardiovascular health.
HBC’s half of the equation, OmeGo Salmon Oil, an omega-3 ingredient, has performed well in clinical trials at lowering a new marker of cardiovascular health, oxLDL beta-2 glycoprotein (GP), according to Matt Mixter, managing director, U.S., HBC. Mixter claims oxLDL GP is a better indicator of cardiac event risk than cholesterol or triglycerides.
The other ingredient, MenaQ7 Pure, is a synthetic vitamin K2 as menaquione-7 (MK-7), which NattoPharma claims “is the most bioavailable K2 available.”
“Mena Q7 Vitamin K2 as MK-7 has been clinically shown to increase arterial flexibility by promoting the most potent inhibitor of arterial calcification: the activation of matrix gla protein (MGP),” says Hogne Vik, CEO, NattoPharma.
The two companies believe this pairing of MenaQ7 and OmeGo will allow for even greater cardiovascular health benefits, in addition to increased “manufacturing ease.”
“Omega-3 has been established as a cardiovascular health ingredient, as it has earned a qualified health claim in the U.S. for the reduction in risk of coronary heart disease,” says Vik. “By balancing calcium metabolism, vitamin K2 offers a potential synergistic role with omega-3 that could result in unsurpassed cardiovascular formulas that also deliver bone health benefits.”
The new blend will be officially launched on March 5 at Expo West.
Michael Crane
Associate Editor
Nutritional Outlook magazine
michael.crane@ubm.com
Photo © iStockphoto.com/angelhell
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.
Recent review makes the case for testing omega-3 fatty acid levels in humans
May 23rd 2024The article commissioned by The Global Organization for EPA and DHA Omega-3s (GOED) reviewed the state of omega-3 fatty acid testing, highlighting the value of testing and the commercially available options for diagnostic testing.
Epax launches concentrated oil that combines omegas 3, 9, and 11
May 10th 2024The blend of long-chain polyunsaturated fatty acids and long-chain monounsaturated fatty acids combines the heart and brain health benefits of omegas-3s with the skin and metabolic health benefits of omegas 9 and 11.